To determine the prognostic significance of anticentromere (ACA) and antitopoisomerase I (anti-topo) in Raynaud's Disease (RD), patients are evaluated, antibodies studied yearly, esophageal transit time (ETT) and pulmonary function tests done in years 1,3,5. Enrollment of patients is complete.
Showing the most recent 10 out of 638 publications